Modern Healthcare June 9, 2017
Shelby Livingston

Paying for certain high-cost drugs based on the patient outcomes they deliver is becoming increasingly necessary in the face of skyrocketing drug costs in the U.S., the CEOs of a health insurance company and a pharmaceutical giant agreed Thursday.

The two industries rarely see eye to eye. Harvard Pilgrim Health Care CEO Eric Schultz and Eli Lilly CEO David Ricks joked Thursday at the 2017 AHIP Institute and Expo in Austin, Texas, that they almost called off their panel discussion for fear of having to sit next to each other. But the two found common ground on value-based agreements.

“We in the health insurance industry have used payment for value, payment for performance, for many years with physicians and hospitals,”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: ACO (Accountable Care), CMS, Health System / Hospital, MACRA, Medicaid, Medicare, Medicare Advantage, Patient / Consumer, Payer, Physician, Primary care, Private Exchange, Provider, Public Exchange, Self-insured, Value Based
Related Articles:
Congressional spending plan: What’s in it for healthcare, and what isn’t
Societal Perceptions Of Health Insurers: Knights, Knaves, Or Pawns?
How 3 hospitals are reimagining behavioral crisis care
How Health Systems Can Collaborate on AI Tools
Critical access hospitals face uphill battle: 6 things to know

Share This Article